Immune Response after SARS-CoV-2 Infection with Residual Post-COVID Symptoms

dc.contributor.authorPongkunakorn T.
dc.contributor.authorManosan T.
dc.contributor.authorSurawit A.
dc.contributor.authorOphakas S.
dc.contributor.authorMongkolsucharitkul P.
dc.contributor.authorPumeiam S.
dc.contributor.authorSuta S.
dc.contributor.authorPinsawas B.
dc.contributor.authorSookrung N.
dc.contributor.authorSaelim N.
dc.contributor.authorMahasongkram K.
dc.contributor.authorPrangtaworn P.
dc.contributor.authorTungtrongchitr A.
dc.contributor.authorTangjittipokin W.
dc.contributor.authorMangmee S.
dc.contributor.authorBoonnak K.
dc.contributor.authorNarkdontri T.
dc.contributor.authorTeerawattanapong N.
dc.contributor.authorWanitphadeedecha R.
dc.contributor.authorMayurasakorn K.
dc.contributor.otherMahidol University
dc.date.accessioned2023-10-04T18:01:48Z
dc.date.available2023-10-04T18:01:48Z
dc.date.issued2023-09-01
dc.description.abstractMany patients develop post-acute COVID syndrome (long COVID (LC)). We compared the immune response of LC and individuals with post-COVID full recovery (HC) during the Omicron pandemic. Two hundred ninety-two patients with confirmed COVID infections from January to May 2022 were enrolled. We observed anti-SARS-CoV-2 receptor-binding domain immunoglobulin G, surrogate virus neutralization test, T cell subsets, and neutralizing antibodies against Wuhan, BA.1, and BA.5 viruses (NeuT). NeuT was markedly reduced against BA.1 and BA.5 in HC and LC groups, while antibodies were more sustained with three doses and an updated booster shot than ≤2-dose vaccinations. The viral neutralization ability declined at >84-days after COVID-19 onset (PC) in both groups. PD1-expressed central and effector memory CD4+ T cells, and central memory CD8+ T cells were reduced in the first months PC in LC. Therefore, booster vaccines may be required sooner after the most recent infection to rescue T cell function for people with symptomatic LC.
dc.identifier.citationVaccines Vol.11 No.9 (2023)
dc.identifier.doi10.3390/vaccines11091413
dc.identifier.eissn2076393X
dc.identifier.scopus2-s2.0-85172255636
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/90295
dc.rights.holderSCOPUS
dc.subjectImmunology and Microbiology
dc.titleImmune Response after SARS-CoV-2 Infection with Residual Post-COVID Symptoms
dc.typeArticle
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85172255636&origin=inward
oaire.citation.issue9
oaire.citation.titleVaccines
oaire.citation.volume11
oairecerif.author.affiliationSiriraj Hospital

Files

Collections